Teitur

Teitur Trophics is a biotechnology company dedicated to developing new treatments for patients with neurodegenerative diseases. It is developing the first cyclic peptides for treating currently untreatable neurodegenerative diseases, including Parkinson's disease, frontotemporal dementia, and Huntington's disease. Teitur’s primary candidate drug, TT-P34, works by clearing toxic protein deposits associated with neurodegenerative diseases, restoring mitochondrial function in affected brain cells, and promoting pro-survival signaling.